Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   191 Trials   191 Trials   19915 News 


«12...158159160161162163164165166167168...203204»
  • ||||||||||  Pauci-Immune Crescentic Glomerulonephritis with Re-Initiation of Adalimumab for Crohn Disease () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5782;    
    For her CD, she was transitioned from adalimumab to vedolizumab (an oral monoclonal antibody with gut selective anti-inflammatory activity) due to concern that adalimumab contributed to her PICG...Discussion The TNFa inhibitors infliximab and etanercept have a rare association with PICG and in renal biopsy case series of patients with a history of IBD PICG has been reported. However, the association of adalimumab with ANCA negative PICG in this case is unique in the literature and may represent an under recognized etiology of glomerulonephritis in IBD.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Enrollment closed, Trial completion date, Trial primary completion date:  RIDD: Repurposing Anti-TNF for Treating Dupuytren's Disease (clinicaltrials.gov) -  Oct 21, 2019   
    P2,  N=209, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Dec 2019 --> Apr 2020
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    TUMOR NECROSIS FACTOR BLOCKING AGENTS REDUCE RISK FOR ALZHEIMER’S DISEASE IN PATIENTS WITH CO-MORBID RHEUMATOID ARTHRITIS AND PSORIASIS. () -  Oct 20, 2019 - Abstract #CTAD2019CTAD_291;    
    Increased risk for AD also was found in patients ≥ 18 years with psoriasis (AOR = 1.37, 95% CI: (1.31-1.42), P-value <0.0001), ankylosing spondylitis (AOR = 1.57, 95% CI: (1.39-1.77), P-value <0.0001), inflammatory bowel disease (AOR = 2.46, 95% CI: (2.33-2.59) ), P-value <0.0001), ulcerative colitis (AOR = 1.82, 95% CI: (1.74-1.91), P-value <0.0001), and Crohn’s disease (AOR = 2.33 95% CI: (2.22-2.43), P-value <0.0001). The risk for AD in patients over 65 years with RA was reduced by treatment with etanercept (AOR = 0.34, 95% CI: (0.25-0.47), P-value <0.0001), adalimumab (AOR = 0.28, 95% CI: (0.19-0.39), P-value <0.0001), in iximab (AOR = 0.52, 95% CI: (0.39-0.69), P-value <0.0001) or methotrexate (AOR = 0.64, 95% CI: (0.61-0.68), P-value <0.0001).
  • ||||||||||  Journal:  The role of biologics in the treatment of chronic granuloma annulare. (Pubmed Central) -  Oct 18, 2019   
    However, the literature is limited to case series lacking control groups. Randomized, controlled trials are required to establish evidence-based treatment of GA and related cutaneous, granulomatous conditions.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    Retrospective data, Review, Journal:  Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis. (Pubmed Central) -  Oct 18, 2019   
    Evidence on the safety of the interventions was inconclusive, however cases of pancreatitis and leukopenia from purine analogues were evident in the studies. Larger trials are needed to further understand the effect of the interventions on endoscopic relapse.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Clinical, Retrospective data, Journal:  Clinical features and therapy of uveitis in childhood (Pubmed Central) -  Oct 17, 2019   
    13 children with severe disease activity required biological therapy (adalimumab injection)...Orv Hetil. 2019; 160(34): 1335-1339.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment. (Pubmed Central) -  Oct 17, 2019   
    Tyr, BMP-4 and melanin content were also evaluated in the psoriatic lesional skin of patients receiving adalimumab therapy, before and after 16 weeks of treatment...The present study confirmed the influence of the psoriatic pro-inflammatory network on melanogenesis, exerting an inhibitory effect mediated by TNF-α. Furthermore, the results regarding BMP-4 in the present study add another important element to the mechanism of psoriasis.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
    Journal:  Ixekizumab superior to adalimumab for PsA. (Pubmed Central) -  Oct 17, 2019   
    Furthermore, the results regarding BMP-4 in the present study add another important element to the mechanism of psoriasis. No abstract available